tetano
Editor, Senior Moderator
Eur J Immunol
. 2021 Mar 27.
doi: 10.1002/eji.202049101. Online ahead of print.
Peptide microarray based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development
Pavlo Holenya[SUP] 1 [/SUP], Paul Joris Lange[SUP] 2 3 4 5 [/SUP], Ulf Reimer[SUP] 1 [/SUP], Wolfram Woltersdorf[SUP] 3 [/SUP], Thomas Panterodt[SUP] 3 [/SUP], Michael Glas[SUP] 3 [/SUP], Mark Wasner[SUP] 3 [/SUP], Maren Eckey[SUP] 1 [/SUP], Michael Drosch[SUP] 1 [/SUP], J?rg-Michael Hollidt[SUP] 2 6 [/SUP], Michael Naumann[SUP] 4 [/SUP], Florian Kern[SUP] 1 7 [/SUP], Holger Wenschuh[SUP] 1 [/SUP], Robert Lange[SUP] 2 3 [/SUP], Karsten Schnatbaum[SUP] 1 [/SUP], Frank F Bier[SUP] 2 5 [/SUP]
Affiliations
Abstract
Humoral immunity to the Severe Adult Respiratory Syndrome (SARS) Coronavirus (CoV)-2 is not fully understood yet but is a crucial factor of immune protection. The possibility of antibody cross-reactivity between SARS-CoV-2 and other human coronaviruses (HCoVs) would have important implications for immune protection but also for the development of specific diagnostic ELISA tests. Using peptide microarrays, n = 24 patient samples and n = 12 control samples were screened for antibodies against the entire SARS-CoV-2 proteome as well as the Spike (S), Nucleocapsid (N), VME1 (V), R1ab, and Protein 3a (AP3A) of the HCoV strains SARS, MERS, OC43 and 229E. While widespread cross-reactivity was revealed across several immunodominant regions of S and N, IgG binding to several SARS-CoV-2-derived peptides provided statistically significant discrimination between COVID-19 patients and controls. Selected target peptides may serve as capture antigens for future, highly COVID-19-specific diagnostic antibody tests. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; SARS-CoV-2; antibody; diagnostics; peptide microarray.
. 2021 Mar 27.
doi: 10.1002/eji.202049101. Online ahead of print.
Peptide microarray based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development
Pavlo Holenya[SUP] 1 [/SUP], Paul Joris Lange[SUP] 2 3 4 5 [/SUP], Ulf Reimer[SUP] 1 [/SUP], Wolfram Woltersdorf[SUP] 3 [/SUP], Thomas Panterodt[SUP] 3 [/SUP], Michael Glas[SUP] 3 [/SUP], Mark Wasner[SUP] 3 [/SUP], Maren Eckey[SUP] 1 [/SUP], Michael Drosch[SUP] 1 [/SUP], J?rg-Michael Hollidt[SUP] 2 6 [/SUP], Michael Naumann[SUP] 4 [/SUP], Florian Kern[SUP] 1 7 [/SUP], Holger Wenschuh[SUP] 1 [/SUP], Robert Lange[SUP] 2 3 [/SUP], Karsten Schnatbaum[SUP] 1 [/SUP], Frank F Bier[SUP] 2 5 [/SUP]
Affiliations
- PMID: 33772767
- DOI: 10.1002/eji.202049101
Abstract
Humoral immunity to the Severe Adult Respiratory Syndrome (SARS) Coronavirus (CoV)-2 is not fully understood yet but is a crucial factor of immune protection. The possibility of antibody cross-reactivity between SARS-CoV-2 and other human coronaviruses (HCoVs) would have important implications for immune protection but also for the development of specific diagnostic ELISA tests. Using peptide microarrays, n = 24 patient samples and n = 12 control samples were screened for antibodies against the entire SARS-CoV-2 proteome as well as the Spike (S), Nucleocapsid (N), VME1 (V), R1ab, and Protein 3a (AP3A) of the HCoV strains SARS, MERS, OC43 and 229E. While widespread cross-reactivity was revealed across several immunodominant regions of S and N, IgG binding to several SARS-CoV-2-derived peptides provided statistically significant discrimination between COVID-19 patients and controls. Selected target peptides may serve as capture antigens for future, highly COVID-19-specific diagnostic antibody tests. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; SARS-CoV-2; antibody; diagnostics; peptide microarray.